BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Novartis Europharm Ltd, U.K. submitted on 7 October 1997, to the European Agency 
for the Evaluation of Medicinal Products (EMEA), an application to obtain Marketing Authorisation 
for  the  medicinal  product  Simulect  in  accordance  with  the  Centralised  Procedure  falling  within  the 
scope  of  Part  A  of  the  Annex  to  Council  Regulation  No  (EC)  2309/93  of  22  July  1993. 
The Rapporteur and the Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  
Prof. Kurth  
from 1 Jan. 1998: Dr. M. Haase  
Co-Rapporteur:  Prof. G. Vicari 
 Licensing status: 
Simulect has been given a marketing authorisation in the following countries:  
U.S. on 12 May 1998, Switzerland on 7 April 1998, Argentina on 29 April 1998. 
2. 
Steps taken for the assessment of the product 
•  The procedure started on 24 October 1997. 
•  The Rapporteur's first assessment report was circulated to all CPMP Members on 7 January 1998. 
•  The  Co-rapporteur's  first  assessment  report  was  circulated 
to  all  CPMP  Members  on  
5 January 1998. 
•  During the CPMP plenary meeting on 23-25 February 1998, the CPMP agreed on the consolidated 
list of questions to be sent to the company. The final consolidated list of questions was sent to the 
Company on 25 February 1998. 
•  The company submitted the responses to the consolidated list of questions on 9 April 1998. 
•  The joint Rapporteur/Co-Rapporteur assessment report on the company’s responses was circulated 
to all CPMP members on 15 May 1998. 
•  The CPMP requested an Inspection of the Manufacturing site of Novartis Pharma AG, Basel and 
Novartis  Pharma  AG,  Stein.  on  the  basis  of  the  need  to  assess  GMP  compliance.  The  inspection 
took place on 30 March - 3 April 1998. The inspection report was forwarded to EMEA on 8 June 
1998.  
The general impression of the Quality Assurance System and compliance with the EU GMP rules 
is positive. 
•  The  BWP  during  their  meeting  on  16  June  1998  prepared  a  recommendation  to  the  CPMP  on 
quality  aspects  of  the  joint  Rapporteur/Co-Rapporteur’s  assessment  report  on  the  company’s 
responses. 
•  The CPMP, during their meeting on 23 June 1998 discussed the recommendations presented by the 
Rapporteur,  considering  the  responses  provided  by  the  company  were  satisfactory.  Amendments 
were discussed to the Summary of Product Characteristics and Package Leaflet texts. 
•  The  CPMP  during  their  meeting  of  21  -  23  June  1998,  issued  a  positive  opinion  for  granting  a 
marketing authorisation to Simulect on 23 June 1998. 
•  The  CPMP  opinion  was  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission which adopted the corresponding Decision on 9 October 1998. 
1/1
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
